TABLE 3.

Trials examining smoking cessation pharmacotherapy in cardiac patients

Study, year	Cardiac population	Sample (n)	Intervention	Duration (weeks)	Time of follow-up (months)	Daily dose (mg)	Biochemical validation
Tonstad et al (30), 2003	CVD (had to have at least one of the following conditions: MI >3 months previously, an interventional cardiac procedure, stable angina, PVD or CHF)	626	Bupropion	7	12	300*	Expired CO
Joseph et al (32), 1996	CVD (history of MI, CABG, angioplasty, stenosis >50%, angina, CHF, arrhythmia, PVD, CVD or cor pulmonale)	584	Nicotine patch	10	6	21 for 6 weeks; 14 for 2 weeks; 7 for 2 weeks	Expired CO
Rigotti et al (31), 2006	Acute CVD (patients admitted with MI or unstable angina, CABG or other cardiovascular conditions with documented CAD)	247	Bupropion	12	12	300*	Saliva cotinine
Campbell et al (36), 1991	In-hospital CVD patients†	85	Nicotine gum	NR‡	12	2§	Expired CO

^*Taken as 150 mg twice daily;

^†Called heart disease in the study, not specified further. Patients with other smoking-related diseases were included (total n=219);

^‡Median duration of gum use was 37 days;

^§Stronger gum (4 mg) was offered for up to 3 months to those still smoking. CABG Coronary artery bypass graft surgery; CHF Congestive heart failure; CO Carbon monoxide; CVD Cardiovascular disease; MI Myocardial infarction; NR Not reported; PVD Peripheral vascular disease